To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Resource Library
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Select year:
Videos
A collection of videos showcased at our ACR 2026 Medical Affairs Booth.
Myositis Disease Pathogenesis Video
This video provides an overview of myositis pathogenesis, including clinical manifestations, disease subtypes, heterogeneity and the role of immunoglobulin G autoantibodies.
Efgartigimod Mechanism of Action Video
An educational resource illustrating efgartigimod's differentiated mechanism of action in an indication-agnostic context.
ReachMD Myositis Expert Interview Podcast
A video and audio podcast featuring argenx-contracted speaker Dr Paik and ReachMD host Dr McDonough, exploring myositis epidemiology and subtypes, as well as the roles of immunoglobulin G autoantibodies, myositis-specific autoantibodies and myositis-associated autoantibodies.
Handouts
Downloadable resources with key insights and clinical trial updates.
Efgartigimod Mechanism of Action Handout
An educational overview of immunoglobulin G antibodies, their role in autoimmune disease and efgartigimod’s proposed mechanism of action. This disease-state–agnostic resource provides additional insight into the scientific rationale underlying efgartigimod and the broader argenx pipeline.
Myositis Disease State Handout
A summary of myositis. It covers clinical manifestations, myositis subtypes, disease burden and the proposed role of immunoglobulin G autoantibodies in myositis pathophysiology.
Immunology Innovation Program Flyer
A resource highlighting what the argenx Immunology Innovation Program (IIP) is, the value of the program and argenx’s approach to collaboration.
Cross-Indication Externally Sponsored Research Handout
A summary of argenx's Externally-sponsored Research (ESR) program, including areas of primary research interest and the Investigator-initiated Study (IIS) process.
Poster/oral presentations 2026
ACR posters will be available following their presentation at the congress.
Poster/oral presentations 2025
Recent developments in the neuromuscular field.
We couldnot find any results for your search.
Please consider trying a different term.
Items per page:
- 3
- 6
- 9
- 12
1-12 of 16
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.
© 2026 argenx MED-US-a119-2600085 v1 10/2026. All Rights Reserved.